Mofisure
Mycophenolic acid delayed-release USP
360 mg · delayed-release tablets
Antiproliferative immunosuppressant, used as part of a maintenance regimen after renal transplant.
At a glance.
| Brand name | Mofisure |
|---|---|
| Composition | Mycophenolic acid delayed-release USP |
| Strength | 360 mg |
| Dosage form | Delayed-release tablets |
| Care segment | Transplant care |
| Pack size | 10 × 10 tablets |
| Storage | TBC — client to supply |
| Schedule | Prescription only Verify schedule |
| Shelf life | TBC — client to supply |
| Manufactured by | TBC — client to supply |
What it is used for.
Antiproliferative immunosuppressant used as part of a maintenance immunosuppressive regimen following renal transplantation.
Indication summary written for orientation only. Full prescribing information, dosing and contraindications are supplied to registered healthcare professionals on request.
Where it sits in the pathway
Related products.
Tacsure 0.5
Tacrolimus IP
0.5 mg · capsules
Calcineurin inhibitor for prophylaxis of organ rejection. Narrow therapeutic index.
Trough level View details Transplant careTacsure 1.0
Tacrolimus IP
1 mg · capsules
The 1 mg presentation, used alone or with the 0.5 mg strength to titrate to target trough.
Trough level View details Transplant careValsure
Valganciclovir hydrochloride USP (eq. to valganciclovir)
450 mg · film-coated tablets
Antiviral used for cytomegalovirus prophylaxis and treatment in transplant recipients.
CMV prophylaxis View detailsNeed this product for a patient this week?
Tell us the unit and the quantity. We will confirm availability and the nearest stockist.